Pages that link to "Q39569476"
Jump to navigation
Jump to search
The following pages link to Regional Differences in the Cellular Immune Response to Experimental Cutaneous or Visceral Infection withLeishmania donovani (Q39569476):
Displaying 49 items.
- Determinants for the development of visceral leishmaniasis disease (Q27027871) (← links)
- Iron overload favors the elimination of Leishmania infantum from mouse tissues through interaction with reactive oxygen and nitrogen species (Q27305261) (← links)
- Combination of liposomal CpG oligodeoxynucleotide 2006 and miltefosine induces strong cell-mediated immunity during experimental visceral leishmaniasis (Q27341915) (← links)
- Combination therapy with indolylquinoline derivative and sodium antimony gluconate cures established visceral leishmaniasis in hamsters (Q28366821) (← links)
- Identification of small molecule lead compounds for visceral leishmaniasis using a novel ex vivo splenic explant model system (Q28477163) (← links)
- Characterization of glycolytic enzymes--rAldolase and rEnolase of Leishmania donovani, identified as Th1 stimulatory proteins, for their immunogenicity and immunoprophylactic efficacies against experimental visceral leishmaniasis (Q28539119) (← links)
- Infrared fluorescent imaging as a potent tool for in vitro, ex vivo and in vivo models of visceral leishmaniasis (Q28545229) (← links)
- Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library (Q30654793) (← links)
- Efficacies of KY62 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous leishmaniasis and visceral leishmaniasis (Q33698601) (← links)
- Vaccination with a Leishmania infantum HSP70-II null mutant confers long-term protective immunity against Leishmania major infection in two mice models (Q33783745) (← links)
- Critical role of IRF-5 in the development of T helper 1 responses to Leishmania donovani infection (Q33799144) (← links)
- Novel arylimidamides for treatment of visceral leishmaniasis (Q33876693) (← links)
- Experimental transmission of Leishmania infantum by two major vectors: a comparison between a viscerotropic and a dermotropic strain (Q33939315) (← links)
- Clinical and experimental advances in treatment of visceral leishmaniasis (Q33982648) (← links)
- Rapid local expression of interleukin-12, tumor necrosis factor alpha, and gamma interferon after cutaneous Francisella tularensis infection in tularemia-immune mice (Q34000875) (← links)
- Leishmania major reaches distant cutaneous sites where it persists transiently while persisting durably in the primary dermal site and its draining lymph node: a study with laboratory mice (Q34005112) (← links)
- Immunomodulatory role of interleukin-10 in visceral leishmaniasis: defective activation of protein kinase C-mediated signal transduction events (Q34006307) (← links)
- Malnutrition alters the innate immune response and increases early visceralization following Leishmania donovani infection (Q34008436) (← links)
- Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis (Q34008441) (← links)
- Gender is a major determinant of the clinical evolution and immune response in hamsters infected with Leishmania spp (Q34121668) (← links)
- Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy (Q34181985) (← links)
- Tissue granuloma structure-function in experimental visceral leishmaniasis (Q34434760) (← links)
- Performance of LBSap vaccine after intradermal challenge with L. infantum and saliva of Lu. longipalpis: immunogenicity and parasitological evaluation (Q34493859) (← links)
- Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis (Q34521577) (← links)
- Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis (Q35165825) (← links)
- Animal models for the analysis of immune responses to leishmaniasis (Q35188674) (← links)
- Regulatory T cells and parasites (Q35665111) (← links)
- Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani (Q36367801) (← links)
- Immunity to a salivary protein of a sand fly vector protects against the fatal outcome of visceral leishmaniasis in a hamster model. (Q36678092) (← links)
- Experimental models in vaccine research: malaria and leishmaniasis (Q37371348) (← links)
- Chemokine gene expression in toll-like receptor-competent and -deficient mice infected with Leishmania major (Q37521995) (← links)
- Polymerase chain reaction detection and inducible nitric-oxide synthase expression of Leishmania major in mice inoculated by two different routes (Q38776366) (← links)
- Characterization of Leishmania isolates from Nepalese patients with visceral leishmaniasis (Q39336044) (← links)
- Immunization with Leishmania infantum released proteins confers partial protection against parasite infection with a predominant Th1 specific immune response. (Q39408268) (← links)
- Cloning of Syrian Hamster (Mesocricetus auratus) Cytokine cDNAs and Analysis of Cytokine mRNA Expression in Experimental Visceral Leishmaniasis (Q39571176) (← links)
- Molecular, biochemical characterization and assessment of immunogenic potential of cofactor-independent phosphoglycerate mutase against Leishmania donovani: a step towards exploring novel vaccine candidate (Q40141972) (← links)
- Selective enhancement of the type 1 cytokine response by expression of a canine interleukin (IL)-12 fused heterodimeric DNA. (Q40335039) (← links)
- Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis (Q43809187) (← links)
- Evaluation of parasitological and immunological parameters of Leishmania chagasi infection in BALB/c mice using different doses and routes of inoculation of parasites. (Q44055512) (← links)
- Vaccination with Liposomal Leishmanial Antigens Adjuvanted with Monophosphoryl Lipid–Trehalose Dicorynomycolate (MPL-TDM) Confers Long-Term Protection against Visceral Leishmaniasis through a Human Administrable Route (Q44634874) (← links)
- Efficacy of Leishmania donovani trypanothione reductase, identified as a potent Th1 stimulatory protein, for its immunogenicity and prophylactic potential against experimental visceral leishmaniasis (Q46290224) (← links)
- Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis (Q46832650) (← links)
- A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice (Q47993991) (← links)
- Non PC liposome entrapped promastigote antigens elicit parasite specific CD8 and CD4 T-cell immune response and protect hamsters against visceral leishmaniasis. (Q51812069) (← links)
- Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs. (Q53609100) (← links)
- Evidence for Seroprevalence in Human Localized Cutaneous Leishmaniasis Caused by Leishmania donovani in Sri Lanka. (Q55030755) (← links)
- High iNOS expression in macrophages in canine leishmaniasis is associated with low intracellular parasite burden (Q81065999) (← links)
- Immunogenicity of a killed Leishmania vaccine with saponin adjuvant in dogs (Q81390259) (← links)
- Effect of dose and route of inoculation on the generation of CD4 Th1/Th2 type of immune response in murine visceral leishmaniasis (Q81886368) (← links)